Journal Article Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1

Toi, Masakazu  ,  Shao, Zhimin  ,  Hurvitz, Sara  ,  Tseng, Ling-Ming  ,  Zhang, Qingyuan  ,  Shen, Kunwei  ,  Liu, Donggeng  ,  Feng, Jifeng  ,  Xu, Binghe  ,  Wang, Xiaojia  ,  Lee, Keun Seok  ,  Ng, Ting Ying  ,  Ridolfi, Antonia  ,  Noel-baron, Florence  ,  Ringeisen, Francois  ,  Jiang, Zefei

192017-04-11 , Springer Nature
ISSN:1465-542X
Description
[Background]The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in the BOLERO-1 trial. [Methods]Postmenopausal women with HER2+ advanced breast cancer, who had not received systemic therapy for advanced disease, were randomized 2:1 to receive everolimus or placebo, plus trastuzumab and paclitaxel. The two primary end points were investigator-assessed progression-free survival (PFS) in the full population and in the hormone receptor-negative (HR–) subpopulation. Secondary end points included assessment of the objective response rate, the clinical benefit rate, and safety. [Results]In the Asian subset, median PFS was similar in the everolimus (n = 198) and placebo (n = 105) arms in the full analysis set (hazard ratio = 0.82 (95% CI 0.61–1.11)). In the HR– subpopulation, everolimus prolonged median PFS by 10.97 months vs placebo (25.46 vs 14.49 months; hazard ratio = 0.48 (95% CI 0.29–0.79)). In the everolimus arm of the Asian subset, the most common adverse events of any grade were stomatitis (62.2%), diarrhea (48.0%), rash (43.4%) and neutropenia (42.3%). Neutropenia (grade 3: 27.6%; grade 4: 4.6%) and decreased neutrophil count (grade 3: 11.2%; grade 4: 3.6%) were the most frequent grade 3/4 adverse events. Serious adverse events included pneumonia (5.1%), pneumonitis (3.1%), and interstitial lung disease (3.1%). There were three deaths (1.5%) during treatment in the everolimus arm vs none in the placebo arm. [Conclusions]The efficacy and safety of everolimus plus trastuzumab and paclitaxel as first-line treatment for HER2+ advanced breast cancer in the Asian subset was consistent with that reported previously in the overall population.
Full-Text

http://repository.kulib.kyoto-u.ac.jp/dspace/bitstream/2433/225253/1/s13058-017-0839-0.pdf

Number of accesses :  

Other information